Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproic Acid and Capecitabine with SCRT in Rectal Cancer
NCT01898104Phase 2Unknown
- Sponsor
- National Cancer Institute
- Start
- May 2012
- Primary completion
- Nov 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valproic acid, capecitabine in rectal cancer, sponsored by National Cancer Institute. Status: unknown.
02
Drugs
valproic acidcapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01898104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01898104.